MCM
RGNX icon

MAI Capital Management’s Regenxbio RGNX Stock Holding History

MAI Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,158
Closed -$9.71K – 4147
2026
Q1 		$9.71K Buy
1,158
+1,039
+873% +$10.9K ﹤0.01% 3196
2025
Q4 		$1.71K Sell
119
-86
-42% -$1.07K ﹤0.01% 3455
2025
Q3 		$1.98K Buy
205
+110
+116% +$973 ﹤0.01% 3314
2025
Q2 		$780 Hold
95
– – ﹤0.01% 3681
2025
Q1 		$680 Hold
95
– – ﹤0.01% 3198
2024
Q4 		$735 Buy
+95
New +$892 ﹤0.01% 3251

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

MAI Capital Management's RGNX Position: Q2 2026 in Review

MAI Capital Management sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 1,158 shares — an estimated $9.71K sold.

MAI Capital Management first reported a position in RGNX in Q4 2024 and held it in 6 quarters. The position peaked at $9.71K in Q1 2026. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • MAI Capital Management reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,158 Regenxbio shares in Q2 2026, an estimated $9.71K.
  • MAI Capital Management first reported a position in Regenxbio in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Regenxbio position peaked at $9.71K in Q1 2026.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.